DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. (DMAC): 4 pipeline candidates · 1 upcoming catalyst · ~16 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.3 months
0% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~166d
N/A
A transparent, data-derived signal for DiaMedica Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$303.4M
Cash
$4.9M
Quarterly Burn
$9.1M
Runway
16.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| DM199 | Phase 2/Phase 3 |
| dm300 | Phase 2/Phase 3 |
| Recombinant human tissue kallikrein | Phase 2/Phase 3 |
| ztalmy | Approved |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
97
Total value held
$79.0M
| Holder | Shares | Value |
|---|---|---|
| cooperman leon g | 2,020,000 | $13.7M |
| blackrock, inc. | 1,856,187 | $12.6M |
| millennium management llc | 935,592 | $6.3M |
| paragon associates & paragon associates ii joint venture | 875,000 | $5.9M |
| geode capital management, llc | 780,516 | $5.3M |
| vanguard capital management llc | 666,912 | $4.5M |
| state street corp | 644,211 | $4.4M |
| first manhattan co. llc. | 455,000 | $3.1M |
| northern trust corp | 338,526 | $2.3M |
| osaic holdings, inc. | 319,675 | $2.2M |
Showing top 10 of 97 institutional holders of DiaMedica Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in DiaMedica Therapeutics Inc.'s pipeline?
DiaMedica Therapeutics Inc. (DMAC) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is DiaMedica Therapeutics Inc.'s lead drug candidate?
DiaMedica Therapeutics Inc.'s most advanced tracked candidate is DM199 (Phase 2/Phase 3) for Pre-Eclampsia.
What is DiaMedica Therapeutics Inc.'s next catalyst?
DiaMedica Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety a" — expected December 1, 2026.
What is DiaMedica Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, DiaMedica Therapeutics Inc. has approximately 16.3 months of cash runway.
What is DiaMedica Therapeutics Inc.'s market capitalization?
DiaMedica Therapeutics Inc.'s market capitalization is approximately $303.4M.
Get the full picture on DiaMedica Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.